keyword
https://read.qxmd.com/read/38527837/-efficacy-and-prognostic-factors-of-allogeneic-hematopoietic-stem-cell-transplantation-in-the-treatment-of-secondary-acute-myeloid-leukemia
#21
MULTICENTER STUDY
X L Yuan, Y B Wu, X L Song, Y Chen, Y Lu, X Y Lai, J M Shi, L Z Liu, Y M Zhao, J Yu, L X Yang, J P Lan, Z Cai, H Huang, Y Luo
Objective: To evaluate the efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with secondary acute myeloid leukemia (sAML) . Methods: In this multicenter, retrospective clinical study, adult patients aged ≥18 years who underwent allo-HSCT for sAML at four centers of the Zhejiang Hematopoietic Stem Cell Transplantation Collaborative Group from January 2014 to November 2022 were included, and the efficacy and prognostic factors of allo-HSCT were analyzed...
January 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38527836/-efficacy-and-safety-of-chimeric-antigen-receptor-t-cell-therapy-followed-by-allogeneic-hematopoietic-stem-cell-transplantation-in-21-patients-with-ph-like-acute-lymphoblastic-leukemia
#22
JOURNAL ARTICLE
H P Dai, H J Shen, Z Li, W Cui, Q Y Cui, M Y Li, S F Chen, M Q Zhu, D P Wu, X W Tang
Objective: To evaluate the efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with Ph-like acute lymphoblastic leukemia (Ph-ALL) . Methods: Patients with Ph-ALL who underwent CAR-T therapy followed by allo-HSCT from March 2018 to August 2023 at the First Affiliated Hospital of Soochow University were included, and their clinical data were retrospectively analyzed. Results: Of the 21 patients, 14 were male and 7 were female...
January 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38527835/-clinical-analysis-of-14-patients-aged-%C3%A2-50-years-with-high-risk-multiple-myeloma-treated-with-allogeneic-hematopoietic-stem-cell-transplantation
#23
JOURNAL ARTICLE
P Pan, J L Wang, W H Zhai, Q L Ma, D L Yang, S Z Feng, M Z Han, A M Pang, E L Jiang
Objective: To evaluate the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in young patients with high-risk multiple myeloma (HRMM) and analyzed the factors affecting patient prognosis. Methods: In this retrospective study, we analyzed the clinical data of 14 patients with HRMM with cytogenetic abnormalities or high-risk biological factors who underwent allo-HSCT at the Hematopoietic Stem Cell Transplantation Center of the Institute of Hematology & Blood Diseases Hospital between November 2016 and November 2022...
January 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38527834/-clinical-features-and-risk-factors-for-invasive-fungal-sinusitis-after-allogeneic-hematopoietic-stem-cell-transplantation
#24
JOURNAL ARTICLE
H X Fu, J J Li, Y Y Zhang, Y Q Sun, X D Mo, T T Han, J Kong, M Lyu, W Han, H Chen, Y Y Chen, F R Wang, C H Yan, Y Chen, J Z Wang, Y Wang, L P Xu, X J Huang, X H Zhang
Objective: To analyze the clinical characteristics and outcomes of patients with invasive fungal sinusitis (invasive fungal rhinosinusitis, IFR) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and explored the risk factors for IFR after allo-HSCT. Methods: Nineteen patients with IFR after allo-HSCT at Peking University People's Hospital from January 2012 to December 2021 were selected as the study group, and 95 patients without IFR after allo-HSCT during this period were randomly selected as the control group (1:5 ratio) ...
January 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38527833/-clinical-outcomes-of-allogeneic-hematopoietic-stem-cell-transplantation-for-chronic-myelomonocytic-leukemia
#25
JOURNAL ARTICLE
X H Zhang, J Y Zhou
Chronic myelomonocytic leukemia (CMML) is a clonal disease derived from bone marrow hematopoietic stem cells, with a poor prognosis. Allogeneic hematopoietic stem cell transplantation (allo- HSCT) is one of the curable methods for CMML. The outcome of patient transplantation is influenced by various factors such as disease characteristics and comorbidities. Based on the existing prognostic stratification system, screening suitable CMML patients for transplantation and early transplantation is beneficial for their long-term survival...
January 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38527499/-chinese-expert-consensus-on-allogeneic-hematopoietic-stem-cell-transplantation-for-cerebral-adrenoleukodystrophy-2023
#26
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
March 25, 2024: Zhonghua Er Ke za Zhi. Chinese Journal of Pediatrics
https://read.qxmd.com/read/38527372/correction-to-microbiota-predict-infections-and-acute-graft-versus-host-disease-after-pediatric-allogeneic-hematopoietic-stem-cell-transplantation
#27
(no author information available yet)
No abstract text is available yet for this article.
March 25, 2024: Journal of Infectious Diseases
https://read.qxmd.com/read/38526183/presentation-anagement-and-outcomes-of-norovirus-in-adult-and-pediatric-solid-organ-and-hematopoietic-stem-cell-transplant-recipients-a-multicenter-retrospective-study
#28
JOURNAL ARTICLE
Michelle Callegari, Lara A Danziger-Isakov, Anne Rose, Daniel Kaul, Kelly Shaffer, Pearlie P Chong, Diana Florescu, Kaci German, Robin Avery, M Hong Nguyen, Brett Wildfeuer, Marian G Michaels, Michael Green, Kexin Guo, Lihui Zhao, Amna Daud, Michael G Ison
BACKGROUND: Norovirus (NoV) can cause chronic relapsing and remitting diarrhea in immunocompromised patients.  Few multicenter studies have described the clinical course, outcomes, and complications of chronic NoV in transplant recipients. METHODS: A multicenter retrospective study of adult and pediatric SOT and HSCT recipients diagnosed with NoV between November 1, 2017, and February 28, 2021. Data were obtained from electronic medical records (EMR) and entered into a central REDCap database...
March 25, 2024: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://read.qxmd.com/read/38526061/performance-evaluation-of-the-high-throughput-quantitative-alinity-m-bk-virus-assay
#29
JOURNAL ARTICLE
Julie W Hirschhorn, Mark M Sasaki, April Kegl, Tanjina Akter, Tanisha Dickerson, Momka Narlieva, Nhi Nhan, Tianxi Liu, Patricia Jim, Stephen Young, Erika Orner, Phyu Thwe, Danijela Lucic, D Yitzchak Goldstein
UNLABELLED: BK virus (BKV) infection or reactivation in immunocompromised individuals can lead to adverse health consequences including BKV-associated nephropathy (BKVAN) in kidney transplant patients and BKV-associated hemorrhagic cystitis (BKV-HC) in allogeneic hematopoietic stem cell transplant recipients. Monitoring BKV viral load plays an important role in post-transplant patient care. This study evaluates the performance of the Alinity m BKV Investigational Use Only (IUO) assay...
March 25, 2024: Journal of Clinical Microbiology
https://read.qxmd.com/read/38525548/autologous-hematopoietic-stem-cells-transplantation-in-mogad
#30
JOURNAL ARTICLE
Sara Mariotto, Sara Carta
No abstract text is available yet for this article.
March 25, 2024: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/38524924/influence-of-diet-and-body-weight-in-treatment-resistant-acquired-partial-lipodystrophy-after-hematopoietic-stem-cell-transplantation-and-its-potential-for-metabolic-improvement
#31
Emi Ishida, Kazuhiko Horiguchi, Shunichi Matsumoto, Atsushi Ozawa, Sho Sekiguchi, Eijiro Yamada
Lipodystrophy is a rare disease characterized by various metabolic complications resulting from the complete or partial loss of adipose tissues and abnormal fat accumulation. Acquired lipodystrophy may occur due to certain drugs, autoimmunity or for unknown reasons. Recently, cases of acquired lipodystrophy after hematopoietic stem cell transplantation (HSCT) have been reported. Leptin administration, used recently to treat generalized lipodystrophy, effectively controlled metabolic complications; however, few reports demonstrated the effectiveness of leptin for acquired partial lipodystrophy...
April 2024: Diabetology International
https://read.qxmd.com/read/38524879/optimal-once-daily-busulfan-administration-in-pediatric-patients-a-simulation-based-investigation-of-intravenous-infusion-times
#32
JOURNAL ARTICLE
Yun Kim, Sungha Moon, Su-Jin Rhee
PURPOSE: Pediatric patients receiving hematopoietic stem cell transplantation undergo regular administration of intravenous busulfan as a conditioning regimen. Once-daily regimen of busulfan has been proposed as a more convenient alternative to the traditional regimen, but it may increase the risk of toxicity such as veno-occlusive disease (VOD). The study aims to evaluate the pharmacokinetics (PKs) of once-daily regimens and investigate appropriate intravenous infusion times to reduce the risk of toxicity...
2024: Drug Design, Development and Therapy
https://read.qxmd.com/read/38523911/case-report-treatment-of-two-cases-of-recurrent-refractory-early-t-cell-precursor-acute-lymphoblastic-leukemia-with-venetoclax-combined-with-the-cag-regimen
#33
Yuxia Jiang, Lin Ji, Xin Jin, Haiying Wu, Mingxia He, Fenglin Shen, Xiaofeng Xu, Huifang Jiang
Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a highly aggressive subtype of T-ALL. No standard chemotherapy regimen exists for patients with recurrent/refractory (R/R) ETP-ALL; in these patients, the primary goal of salvage therapy is to achieve remission as a foundation for consolidation and intensification treatments. This study reports cases of two patients with R/R ETP-ALL who underwent salvage therapy of venetoclax combined with the CAG regimen and achieved complete remission in the bone marrow...
2024: Frontiers in Medicine
https://read.qxmd.com/read/38523199/sustained-remission-after-cord-blood-transplantation-for-breast-cancer-with-lung-metastases-and-myelodysplastic-syndrome
#34
JOURNAL ARTICLE
Naokazu Nakamura, Nao Yamamoto, Tadakazu Kondo, Mayumi Matsumoto, Ryo Ikunari, Tomomi Sakai, Yasuhiro Tanaka, Hiroko Tsunemine, June Takeda, Junya Kanda, Yasuhito Nannya, Seishi Ogawa, Akifumi Takaori-Kondo, Nobuyoshi Arima
Allogenic hematopoietic stem cell transplantation (allo-HSCT) is not a standard therapy for solid cancer because of its high toxicity and insufficient evidence levels. However, the potential graft-versus-solid-tumor (GVT) effect of this therapy has been discussed. Many case reports have also described treatment effects of allo-HSCT in patients with hematologic malignancies and active solid tumors. A 38-year-old woman treated with fulvestrant and abemaciclib for recurrent breast cancer with multiple lung metastases was diagnosed with myelodysplastic syndrome (MDS) with increased blasts 2...
March 25, 2024: International Journal of Hematology
https://read.qxmd.com/read/38522579/cystatin-c-outperforms-creatinine-in-predicting-cefepime-clearance-in-pediatric-stem-cell-transplant-recipients
#35
JOURNAL ARTICLE
H Rhodes Hambrick, Lin Fei, Kathryn Pavia, Jennifer Kaplan, Tomoyuki Mizuno, Peter Tang, Erin Schuler, Stefanie Benoit, Sonya Tang Girdwood
BACKGROUND: Pediatric hematopoietic stem cell transplant (HSCT) patients are at risk of developing both sepsis and altered kidney function. Cefepime is used for empiric coverage post-HSCT and requires dose adjustment based on kidney function. Since cefepime's anti-microbial efficacy is determined by the time free concentrations exceed bacterial minimum inhibitory concentration (MIC), it is important to assess kidney function accurately to ensure adequate concentrations. Serum creatinine (SCr) is routinely used to estimate glomerular filtration rate (eGFR) but varies with muscle mass, which can be significantly lower in HSCT patients, making SCr an inaccurate kidney function biomarker...
March 22, 2024: Transplantation and cellular therapy
https://read.qxmd.com/read/38522578/the-role-of-molecular-or-cytogenetic-response-as-a-favorable-prognostic-factor-before-hematopoietic-stem-cell-transplantation-for-chronic-myeloid-leukemia
#36
JOURNAL ARTICLE
Giuliana Rosendo de Oliveira Medeiros, Vaneuza Araújo Moreira Funke, Alberto Cardoso Martins Lima, Ana Lúcia Vieira Mion, Isabela Menezes, Daniela Carinhanha Setubal, Caroline Bonamin Dos Santos Sola, Gláucia Tagliari, Rafael Marchesini, Samir Kanaan Nabhan, Ricardo Pasquini
Tyrosine kinase inhibitors (TKIs) have revolutionized therapy for patients with chronic myeloid leukemia (CML) over the last two decades. However, some patients still do not achieve an adequate response to these drugs, and hematopoietic stem cell transplantation (HSCT) is indicated in this scenario. We present the results of a 20-year follow-up study of 70 patients who underwent transplantation after TKI failure. The primary objective of the study was to evaluate overall survival (OS) and the secondary objective was to evaluate the outcomes of relapse-free survival (RFS), GVHD-free, relapse-free survival (GFRS) and the incidences of relapse (RI), non-relapse mortality (NRM), acute and chronic GVHD...
March 22, 2024: Transplantation and cellular therapy
https://read.qxmd.com/read/38521840/post-marketing-surveillance-of-the-safety-and-effectiveness-of-nivolumab-for-classic-hodgkin-lymphoma-in-japan
#37
JOURNAL ARTICLE
Akira Kawasaki, Kiyohiko Hatake, Itaru Matsumura, Koji Izutsu, Tomohiro Hoshino, Ayumi Akamatsu, Akito Kakuuchi, Kensei Tobinai
Nivolumab was approved for relapsed/refractory classic Hodgkin lymphoma (cHL) in Japan in 2016. After its approval, a prospective, non-interventional, observational post-marketing surveillance was initiated to evaluate the safety and effectiveness of nivolumab treatment for up to 12 months in patients with relapsed/refractory cHL. Of 304 registered patients, 288 were included in safety analyses and 282 in effectiveness analyses. There were 191 (66.3%) male patients, median age was 64.0 years, and 54 patients (18...
March 23, 2024: International Journal of Hematology
https://read.qxmd.com/read/38521608/impact-of-fda-s-hct-p-zikv-recommendations-on-cord-blood-unit-eligibility-and-utilization-in-a-large-public-cord-blood-bank
#38
JOURNAL ARTICLE
Dana S Guggenheim, Joanne Kurtzberg, Beth H Shaz
BACKGROUND: Cord blood units (CBUs) that are ineligible for licensure due to incomplete compliance with FDA recommendations may be used for hematopoietic stem cell transplantation under urgent medical need and an Investigational Drug Application. The largest reason for CBU donor ineligibility is Zika virus (ZIKV) risk. The study's objective was to analyze the impact of current FDA recommendations for ZIKA risk on a large public cord blood bank and propose updated recommendations. METHODS: We performed a retrospective analysis of Carolinas Cord Blood Bank (CCBB), an FDA licensed public CBB, using data from January 1, 2016 to November 21, 2023 and compared FDA recommendations for transfusion transmitted infections (TTI) for blood products and relevant communicable disease agents or diseases for human cell, tissue, or cellular or tissue-based products (HCT/Ps)...
March 23, 2024: Stem Cells Translational Medicine
https://read.qxmd.com/read/38521410/use-of-eculizumab-in-pediatric-patients-with-high-risk-transplant-associated-thrombotic-microangiopathy-outcomes-and-risk-factors-associated-with-response-and-survival-a-retrospective-study-on-behalf-of-the-spanish-group-for-hematopoietic-transplantation-and
#39
JOURNAL ARTICLE
M I Benítez-Carabante, D Bueno, L Alonso García, I López Torija, J Marsal, Fernandez NavarroJM, M L Uria Oficialdegui, M Panesso, B Molina, C Beléndez Bieler, P Palomo, A Pérez Martínez, C Diaz-de-Heredia
INTRODUCTION: Transplant-associated thrombotic microangiopathy (TA-TMA) is associated with high morbidity and mortality. Although with the introduction of eculizumab the survival has significantly improved, there is still a need for improvement, especially in high-risk patients. OBJECTIVES: This study aims to describe the results obtained with eculizumab in a pediatric cohort with the attempt to define which risk factors could determine the response to treatment...
March 21, 2024: Transplantation and cellular therapy
https://read.qxmd.com/read/38520796/eltrombopag-treatment-in-thrombocytopenia-following-hematopoietic-stem-cell-transplantation-a-multicenter-real-world-experience
#40
JOURNAL ARTICLE
Ebru Kilic Gunes, Sureyya Yigit Kaya, Fatih Yaman, Mustafa Kemal Yeniay, Kurtulus Vural, Melda Comert, Omur Gokmen Sevindik, Neslihan Andic, Simten Dagdas, Ilknur Nizam Ozen, Leylagul Kaynar, Filiz Yavasoglu, Gulsum Ozet, Volkan Karakus, Meltem Ayli
INTRODUCTION: Thrombocytopenia is among the most common complications following hematopoietic stem cell transplantation and is associated with increased mortality and morbidity with no standard treatment yet. In this multicenter and retrospective study, we aim to present our multi-center experience of Eltrombopag treatment in patients with isolated thrombocytopenia following HSCT. MATERIAL-METHOD: A total of 73 patients from 5 centers who underwent autologous or allogeneic stem cell transplantation, had no primary disease relapse, all of whom had neutrophil engraftment, complete chimerism, and who were diagnosed with Prolonged Isolated Thrombocytopenia (PIT) or Secondary Failure Of Platelet Recovery (SFPR) were included in the study...
March 15, 2024: Leukemia Research
keyword
keyword
11336
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.